A Study of ASP2215 (Gilteritinib) by Itself ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy

  • STATUS
    Not Recruiting
  • End date
    Aug 27, 2023
  • participants needed
    250
  • sponsor
    Astellas Pharma Global Development, Inc.
Updated on 13 June 2021
cancer
tyrosine
carbon monoxide
ejection fraction
potassium
induction chemotherapy
azacitidine

Summary

This is a clinical study for adult patients who have recently been diagnosed with acute myeloid leukemia or AML. AML is a type of cancer. It is when bone marrow makes white blood cells that are not normal. These are called leukemia cells. Some patients with AML have a mutation, or change, in the FLT3 gene. This gene helps leukemia cells make a protein called FLT3. This protein causes the leukemia cells to grow faster.

For patients with AML who cannot receive standard chemotherapy, azacitidine (also known as Vidaza) is a current standard of care treatment option in the United States. This clinical study is testing an experimental medicine called ASP2215, also known as gilteritinib. Gilteritinib works by stopping the leukemia cells from making the FLT3 protein. This can help stop the leukemia cells from growing faster.

This study will compare two different treatments. Patients are assigned to one of these two groups by chance: a medicine called azacitidine, also known as Vidaza, or an experimental medicine gilteritinib in combination with azacitidine. There is a twice as much chance to receive both medicines combined than azacitidine alone. The clinical study may help show which treatment helps patients live longer.

Description

Patients considered an adult according to local regulation at the time of obtaining informed consent may participate in the study.

Safety Cohort Prior to initiation of the randomized trial, 8 to 12 patients will be enrolled to evaluate the safety and tolerability of ASP2215 given with azacitidine therapy in the study population.

Randomized Trial Approximately 250 patients will be randomized in a 2:1 ratio to receive ASP2215 plus azacitidine (Arm AC) or azacitidine only (Arm C). Patients will enter the screening period up to 14 days prior to the start of treatment. Patients will be administered treatment over 28-day cycles.

Earlier protocol versions included a 1:1:1 randomization ratio to receive Arm A: ASP2215, Arm AC: ASP2215 + azacitidine or Arm C: azacitidine. Patients previously randomized to Arm A should continue following treatment and assessments as outlined in the protocol.

Details
Condition Acute myeloid leukemia, Acute Myelogenous Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation, Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation, Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation, Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation, Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation, Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation, Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation, Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation, Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation, Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation, Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation, Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation, Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation, Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation, Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation, Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation, Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation, Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation, Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation, Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation, Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation, Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation, Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation, Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation, Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation, Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation, Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation, Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation, Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation, Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation, Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation, Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation, Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation, Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation, Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation, Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation, Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation, Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation, Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation, Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation, acute myelogenous leukemia, anll, acute myeloblastic leukemia, Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation, Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation, Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation, Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation, Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation, Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation, Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
Treatment Azacitidine, Gilteritinib
Clinical Study IdentifierNCT02752035
SponsorAstellas Pharma Global Development, Inc.
Last Modified on13 June 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note